• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

CoraLite® Plus 488-conjugated PEX14 Polyclonal antibody

PEX14 Polyclonal Antibody for FC (Intra), IF/ICC

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

FC (Intra), IF/ICC

Conjugate

CoraLite® Plus 488 Fluorescent Dye

Cat No : CL488-10594

Print datasheet

Synonyms

Cell and organelle markers, dJ734G22.2, NAPP2, Peroxin 14, Peroxisome Marker, PEX14, Pex14p, PTS1 receptor docking protein

验证数据展示

  • IF Staining of HeLa using CL488-10594

    IF Staining of HeLa using CL488-10594

    Immunofluorescent analysis of (4% PFA) fixed HeLa cells using CoraLite® Plus 488 PEX14 antibody (CL488-10594) at dilution of 1:400, CoraLite®594 Beta Actin antibody (CL594-66009, Clone: 2D4H5, red).

  • FC experiment of HeLa using CL488-10594

    FC experiment of HeLa using CL488-10594

    1X10^6 HeLa cells were intracellularly stained with 0.4 ug CoraLite® Plus 488 Anti-Human PEX14 (CL488-10594) (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).

经过测试的应用

Positive IF detected inHeLa cells, HepG2 cells
Positive FC detected inHeLa cells
For other applications, we recommend the unconjugated version of this antibody, 10594-1-AP

推荐稀释比

ApplicationDilution
Immunofluorescence (IF)IF : 1:200-1:800
Flow Cytometry (FC)FC : 0.40 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

发表文章中的应用

IFSee 1 publications below

产品信息

CL488-10594 targets PEX14 in IF, FC (Intra) applications and shows reactivity with human, mouse, rat samples.

Tested Applications FC (Intra), IF/ICC
Cited ApplicationsIF
Tested Reactivity human, mouse, rat
Cited Reactivitymouse
Immunogen PEX14 fusion protein Ag0932 种属同源性预测
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Full Name peroxisomal biogenesis factor 14
Synonyms Cell and organelle markers, dJ734G22.2, NAPP2, Peroxin 14, Peroxisome Marker, PEX14, Pex14p, PTS1 receptor docking protein
Calculated Molecular Weight 41 kDa
Observed Molecular Weight 57 kDa
GenBank Accession NumberBC006327
Gene Symbol PEX14
Gene ID (NCBI) 5195
RRIDAB_2918988
Conjugate CoraLite® Plus 488 Fluorescent Dye
Excitation/Emission Maxima Wavelengths493 nm / 522 nm
Form Liquid
Purification MethodAntigen affinity purification
UNIPROT IDO75381
Storage Buffer PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
Storage ConditionsStore at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

PEX14 (peroxisomal biogenesis factor 14) is a peroxisomal membrane protein that is essential for protein docking onto the peroxisomes. It is a central component of the peroxisimal matrix protein import machinery and interacts with PEX5 and PEX19. PEX14 is ubiquitously expressed and defects in PEX14 are the cause of peroxisome biogenesis disorder complementation group K (PBD-CGK). This antibody can be used to detect endogenous PEX14 with an apparent molecular weight of 57 kDa (PMID: 16449325; 9653144) and recognize peroxisomal structures in human, monkey and mouse cells.

实验方案

Product Specific Protocols
IF protocol for CL Plus 488 PEX14 antibody CL488-10594Download protocol
FC protocol for CL Plus 488 PEX14 antibody CL488-10594Download protocol
Standard Protocols
Click here to view our Standard Protocols

发表文章

SpeciesApplicationTitle
mouseIF

J Neuroinflammation

TRIM45 aggravates microglia pyroptosis via Atg5/NLRP3 axis in septic encephalopathy

Authors - Xuliang Huang
View Article